CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 5 (2024) Vis Cancer Med, 5 (2024) 6 References
Open Access
Review
Issue
Vis Cancer Med
Volume 5, 2024
Article Number 6
Number of page(s) 14
DOI https://doi.org/10.1051/vcm/2024007
Published online 22 July 2024
  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. [CrossRef] [PubMed] [Google Scholar]
  2. Zhang X, Marjani SL, Hu Z, Weissman SM, Pan X, Wu S. Single-cell sequencing for precise cancer research: progress and prospects. Cancer Research. 2016;76:1305–1312. [CrossRef] [PubMed] [Google Scholar]
  3. Liguoro D, Fattore L, Mancini R, Ciliberto G. Drug tolerance to target therapy in melanoma revealed at single cell level: what next?. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020;1874:188440. [CrossRef] [Google Scholar]
  4. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, et al. Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in glioblastoma. Cancer Cell. 2016;29:563–573. [CrossRef] [PubMed] [Google Scholar]
  5. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349:1351–1356. [CrossRef] [PubMed] [Google Scholar]
  6. Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB, Behjati S, et al. Intra-tumour diversification in colorectal cancer at the single-cell level. Nature. 2018;556:457. [CrossRef] [PubMed] [Google Scholar]
  7. Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clinical Cancer Research. 2014;20:2516–2522. [CrossRef] [PubMed] [Google Scholar]
  8. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-Related Cancer. 2013;20:R83–R99. [CrossRef] [PubMed] [Google Scholar]
  9. Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clinical Cancer Research. 2013;19:1933–1940. [CrossRef] [PubMed] [Google Scholar]
  10. Jing H, Lee S. NF-kappa B in cellular senescence and cancer treatment. Molecules and Cells. 2014;37:189–195. [CrossRef] [PubMed] [Google Scholar]
  11. De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opinion on Therapeutic Targets. 2012;16:S17–S27. [CrossRef] [PubMed] [Google Scholar]
  12. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discovery. 2014;4:94–109. [CrossRef] [PubMed] [Google Scholar]
  13. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, et al. beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 2011;20:741–754. [CrossRef] [PubMed] [Google Scholar]
  14. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–3310. [CrossRef] [PubMed] [Google Scholar]
  15. Ma D, Fang Q, Wang P, Gao R, Wu W, Lu T, et al. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells. The Journal of Biological Chemistry. 2015;290:12558–12571. [CrossRef] [PubMed] [Google Scholar]
  16. Yao Y, Wang Y, Chen L, Tian Z, Yang G, Wang R, et al. Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC. Signal Transduction and Targeted Therapy. 2022;7:73. [Google Scholar]
  17. Du Y, Dai J, Mao L, Wei X, Bai X, Chen L, et al. Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma. Journal of the European Academy of Dermatology and Venereology: JEADV. 2024;38:93–101. [CrossRef] [PubMed] [Google Scholar]
  18. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology. 2014;4:64. [CrossRef] [PubMed] [Google Scholar]
  19. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nature Reviews Drug Discovery. 2014;13:140–156. [CrossRef] [PubMed] [Google Scholar]
  20. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. 2016;6:202–216. [CrossRef] [PubMed] [Google Scholar]
  21. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discovery. 2014;4:554–563. [CrossRef] [PubMed] [Google Scholar]
  22. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395–402. [CrossRef] [PubMed] [Google Scholar]
  23. O’Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Translational Oncology. 2010;3:65–79. [CrossRef] [PubMed] [Google Scholar]
  24. Raphael J, Desautels D, Pritchard KI, Petkova E, Shah PS. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: a systematic review and meta-analysis. European Journal of Cancer (Oxford, England: 1990). 2018;91:38–46. [CrossRef] [Google Scholar]
  25. Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, et al. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. Journal of Hematology & Oncology. 2018;11:71. [CrossRef] [PubMed] [Google Scholar]
  26. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nature Reviews Cancer. 2014;14:736–746. [CrossRef] [PubMed] [Google Scholar]
  27. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397. [CrossRef] [PubMed] [Google Scholar]
  28. Groner B, von Manstein V. Jak Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Molecular and Cellular Endocrinology. 2017;451:1–14. [CrossRef] [PubMed] [Google Scholar]
  29. Marotta LLC, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(−) stem cell-like breast cancer cells in human tumors. Journal of Clinical Investigation. 2011;121:2723–2735. [CrossRef] [PubMed] [Google Scholar]
  30. Vafaizadeh V, Klemmt P, Brendel C, Weber K, Doebele C, Britt K, et al. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells. 2010;28:928–938. [CrossRef] [PubMed] [Google Scholar]
  31. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601–2613. [CrossRef] [PubMed] [Google Scholar]
  32. Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H, et al. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clinical Cancer Research. 2013;19:6484–6494. [CrossRef] [PubMed] [Google Scholar]
  33. Lou W, Ni ZY, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate. 2000;42:239–242. [CrossRef] [PubMed] [Google Scholar]
  34. Lu XH, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:18962–18967. [PubMed] [Google Scholar]
  35. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489:155–159. [CrossRef] [PubMed] [Google Scholar]
  36. Tu B, Zhu J, Liu S, Wang L, Fan Q, Hao Y, et al. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3. Oncotarget. 2016;7:48296–48308. [CrossRef] [PubMed] [Google Scholar]
  37. von Manstein V, Groner B. Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib. Medchemcomm. 2017;8:96–102. [CrossRef] [PubMed] [Google Scholar]
  38. Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Molecular Cancer. 2017;16:41. [CrossRef] [PubMed] [Google Scholar]
  39. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nature Reviews Clinical Oncology. 2018;15:81–94. [CrossRef] [PubMed] [Google Scholar]
  40. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343:72–76. [CrossRef] [PubMed] [Google Scholar]
  41. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. New England Journal of Medicine. 2017;376:2109–2121. [CrossRef] [PubMed] [Google Scholar]
  42. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. 2012;13:239–246. [CrossRef] [Google Scholar]
  43. Pailler E, Faugeroux V, Oulhen M, Mezquita L, Laporte M, Honore A, et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer. Clinical Cancer Research. 2019;25:6671–6682. [CrossRef] [PubMed] [Google Scholar]
  44. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine. 2011;3:75ra26. [CrossRef] [PubMed] [Google Scholar]
  45. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043. [CrossRef] [PubMed] [Google Scholar]
  46. Turke AB, Zejnullahu K, Wu Y-L, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77–88. [CrossRef] [PubMed] [Google Scholar]
  47. Lee J-K, Lee J, Kim S, Kim S, Youk J, Park S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. Journal of Clinical Oncology. 2017;35:3065. [CrossRef] [PubMed] [Google Scholar]
  48. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. New England Journal of Medicine. 2016;375:819–829. [CrossRef] [PubMed] [Google Scholar]
  49. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48–61. [CrossRef] [PubMed] [Google Scholar]
  50. Tirosh I, Izar B, Prakadan SM, Wadsworth MH II, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189–196. [CrossRef] [PubMed] [Google Scholar]
  51. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:3041–3046. [CrossRef] [PubMed] [Google Scholar]
  52. Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, et al. The molecular diversity of Luminal A breast tumors. Breast Cancer Research and Treatment. 2013;141:409–420. [CrossRef] [PubMed] [Google Scholar]
  53. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nature Reviews Genetics. 2006;7:21–33. [CrossRef] [PubMed] [Google Scholar]
  54. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine. 2010;363:2424–2433. [CrossRef] [PubMed] [Google Scholar]
  55. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262–1266. [CrossRef] [PubMed] [Google Scholar]
  56. Yang X, Lyer AK, Singh A, Choy E, Hornicek FJ, Amiji MM, et al. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Scientific Reports. 2015;5:8509. [CrossRef] [PubMed] [Google Scholar]
  57. Tada Y, Wada M, Kuroiwa K, Kinugawa N, Harada T, Nagayama J, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clinical Cancer Research. 2000;6:4618–4627. [PubMed] [Google Scholar]
  58. Zhu G, Shi R, Li Y, Zhang Z, Xu S, Chen C, et al. ARID1A, ARID1B, and ARID2 mutations serve as potential biomarkers for immune checkpoint blockade in patients with non-small cell lung cancer. Frontiers in Immunology. 2021;12:670040. [CrossRef] [PubMed] [Google Scholar]
  59. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics. 2019;51:202–206. [CrossRef] [PubMed] [Google Scholar]
  60. Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, et al. Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract cancer: a phase II T1219 study. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2022;28:4248–4257. [CrossRef] [PubMed] [Google Scholar]
  61. Lee M, Li J, Li J, Fang S, Zhang J, Vo ATT, et al. Tet2 inactivation enhances the antitumor activity of tumor-infiltrating lymphocytes. Cancer Research. 2021;81:1965–1976. [CrossRef] [PubMed] [Google Scholar]
  62. Ladle BH, Li KP, Phillips MJ, Pucsek AB, Haile A, Powell JD, et al. De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8 + T-cell fate decisions following activation. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:10631–10636. [CrossRef] [PubMed] [Google Scholar]
  63. Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nature Immunology. 2016;17:95–103. [CrossRef] [PubMed] [Google Scholar]
  64. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Cacerescortes J, et al. A cell initiating human acute myeloid-leukemia after transplantation into scid mice. Nature. 1994;367:645–648. [CrossRef] [PubMed] [Google Scholar]
  65. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:3983–3988. [CrossRef] [PubMed] [Google Scholar]
  66. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. Plos One. 2008;3:e3077. [CrossRef] [PubMed] [Google Scholar]
  67. Alvero AB, Chen R, Fu H-H, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle. 2009;8:158–166. [CrossRef] [PubMed] [Google Scholar]
  68. Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Research. 2012;72:2844–2854. [CrossRef] [PubMed] [Google Scholar]
  69. de Sousa e Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature. 2017;543:676. [CrossRef] [PubMed] [Google Scholar]
  70. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer. 2008;8:755–768. [CrossRef] [PubMed] [Google Scholar]
  71. Zomer A, Ellenbroek SIJ, Ritsma L, Beerling E, Vrisekoop N, Van Rheenen J. Brief report: intravital imaging of cancer stem cell plasticity in mammary tumors. Stem Cells. 2013;31:602–606. [CrossRef] [PubMed] [Google Scholar]
  72. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013;154:61–74. [CrossRef] [PubMed] [Google Scholar]
  73. Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cells – from concept to clinical application. Cancer Letters. 2013;338:32–40. [CrossRef] [PubMed] [Google Scholar]
  74. Boo L, Ho WY, Ali NM, Yeap SK, Ky H, Chan KG, et al. MiRNA transcriptome profiling of spheroid-enriched cells with cancer stem cell properties in human breast MCF-7 cell line. International Journal of Biological Sciences. 2016;12:427–445. [CrossRef] [PubMed] [Google Scholar]
  75. Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature Communications. 2018;9:2897. [CrossRef] [PubMed] [Google Scholar]
  76. Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metabolism. 2017;26:633–647. [CrossRef] [PubMed] [Google Scholar]
  77. Fiorillo M, Verre AF, Iliut M, Peiris-Pages M, Ozsvari B, Gandara R, et al. Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”. Oncotarget. 2015;6:3553–3562. [CrossRef] [PubMed] [Google Scholar]
  78. Sarvi S, Mackinnon AC, Avlonitis N, Bradley M, Rintoul RC, Rassl DM, et al. CD133 + cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Research. 2014;74:1554–1565. [CrossRef] [PubMed] [Google Scholar]
  79. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014;33:1316–1324. [CrossRef] [PubMed] [Google Scholar]
  80. Hong M, Tao S, Zhang L, Diao LT, Huang X, Huang S, et al. RNA sequencing: new technologies and applications in cancer research. Journal of Hematology & Oncology. 2020;13:166. [CrossRef] [PubMed] [Google Scholar]
  81. Lee J, Hyeon DY, Hwang D. Single-cell multiomics: technologies and data analysis methods. Experimental & Molecular Medicine. 2020;52:1428–1442. [CrossRef] [PubMed] [Google Scholar]
  82. Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, NY). 2016;352:189–196. [CrossRef] [PubMed] [Google Scholar]
  83. Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nature Methods. 2009;6:377–382. [CrossRef] [PubMed] [Google Scholar]
  84. Rao A, Barkley D, França GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596:211–220. [CrossRef] [PubMed] [Google Scholar]
  85. Ståhl PL, Salmén F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science (New York, NY). 2016;353:78–82. [CrossRef] [PubMed] [Google Scholar]
  86. Crosetto N, Bienko M, van Oudenaarden A. Spatially resolved transcriptomics and beyond. Nature Reviews Genetics. 2015;16:57–66. [CrossRef] [PubMed] [Google Scholar]
  87. Li R, Liu X, Huang X, Zhang D, Chen Z, Zhang J, et al. Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis. Gut. 2024;73:470–484. [PubMed] [Google Scholar]
  88. Tang Y, Kwiatkowski DJ, Henske EP. Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment. Nature Communications. 2022;13:5018. [CrossRef] [PubMed] [Google Scholar]
  89. Chen WX, Liu XM, Lv MM, Chen L, Zhao JH, Zhong SL, et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One. 2014;9:e95240. [CrossRef] [PubMed] [Google Scholar]
  90. Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, et al. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Oncogene. 2018;37:3806–3821. [CrossRef] [PubMed] [Google Scholar]
  91. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. Journal of Proteomics. 2010;73:1907–1920. [CrossRef] [PubMed] [Google Scholar]
  92. Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014;159:499–513. [CrossRef] [PubMed] [Google Scholar]
  93. Ye H, Wang RY, Yu XZ, Wu YK, Yang BW, Ao MY, et al. Exosomal circNFIX promotes angiogenesis in ovarian cancer via miR-518a-3p/TRIM44 axis. The Kaohsiung Journal of Medical Sciences. 2023;39:26–39. [CrossRef] [PubMed] [Google Scholar]
  94. Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2017;36:1770–1778. [CrossRef] [PubMed] [Google Scholar]
  95. Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124:555–566. [CrossRef] [PubMed] [Google Scholar]
  96. Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bryune E, et al. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Molecular Cancer Therapeutics. 2013;12:1763–1773. [CrossRef] [PubMed] [Google Scholar]
  97. Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, et al. MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Scientific Reports. 2017;7:42339. [CrossRef] [PubMed] [Google Scholar]
  98. Kun-Peng Z, Xiao-Long M, Chun-Lin Z. Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. International Journal of Biological Sciences. 2018;14:321–330. [CrossRef] [PubMed] [Google Scholar]
  99. Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29:653–668. [CrossRef] [PubMed] [Google Scholar]
  100. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interieukin-2. Cancer Research. 2007;67:7458–7466. [CrossRef] [PubMed] [Google Scholar]
  101. Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P, et al. Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib. International Journal of Oncology. 2021;58:238–250. [Google Scholar]
  102. Lundy SK, Klinker MW, Fox DA. Killer B lymphocytes and their Fas ligand positive exosomes as inducers of immune tolerance. Frontiers in Immunology. 2015;6:122. [CrossRef] [PubMed] [Google Scholar]
  103. Xiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, et al. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-kappa B to IL-6 signaling axis and STAT3-driven cancer phenotypes. Science Signaling. 2014;7:ra11. [CrossRef] [PubMed] [Google Scholar]
  104. Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D, et al. The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia. 2015;17:239–255. [CrossRef] [PubMed] [Google Scholar]
  105. Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016;12:655–664. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.